Posted: October 11th, 2022
Tinnus Enterprises LLC and Zuru Inc. v. [x] International, Court of Appeal The Hague, The Netherlands, 20 September 2022, Case no. ECLI:NL:GHDHA:2022:1802 Tinnus holds EP 3 005 948 B1 (hereinafter: EP 948 or the patent). EP 948, entitled ‘Apparatus, system and method for filling containers with fluids’ is licensed to Zuru which markets a toy […]
READ MOREPosted: July 23rd, 2022
Sandoz Limited v Bristol-Myers Squibb Holdings Ireland Unlimited Company and Pfizer Inc. heard together with Teva Pharmaceutical Industries Limited v Bristol-Myers Squibb Holdings Ireland Unlimited Company and Pfizer Inc. v Teva UK Limited (Part 20 Defendant), High Court, London, UK, 15 July 2022, [2022] EWHC 1831 (Pat) Bristol-Myers Squibb and Pfizer’s formulation patents protecting formulations […]
READ MOREPosted: July 12th, 2022
In an interim relief decision of 21 June 2022, the preliminary injunction (PI) Judge of the District Court of The Hague held Novartis’ EP 2 959 894 (“EP 894”) re fingolimod 0,5 mg provisionally invalid. This is the first substantive PI decision on the validity of EP 894 matter in Europe, where several proceedings between […]
READ MOREPosted: July 7th, 2022
Alcon Research LLC and another v Pharmathen SA and Aspire Pharma Limited, Court of Appeal, London, UK, 28 June 2022, [2022] EWCA Civ 845 The English Court of Appeal (Lord Justice Arnold giving the leading judgment with whom Lady Justice King and Lord Justice Nugee agreed) has rejected an appeal by Aspire Pharma Limited (“Aspire”) […]
READ MOREPosted: July 6th, 2022
Overview In two actions that were heard together, Teva and Sandoz (‘the Claimants’) sought revocation of Astellas’ patent EP (UK) 1 559 427 B1 (‘the Patent’). The patent relates to a compound mirabegron (sold under the name Betmiga) which is used to treat overactive bladder (OAB). Mirabegron is a β3 adrenoreceptor (“β3-AR”) agonist. Astellas counterclaimed […]
READ MOREPosted: March 30th, 2022
Judgment handed down in the last of the technical trials in Optis v Apple saga: Optis succeeds in arguing that its patents are valid and infringed by Apple Overview The 15 March 2022 judgment of Mr Justice Meade is the latest in the Optis v Apple saga. It is the last in the series of […]
READ MOREPosted: November 29th, 2021
Erasmus MC and Invivo v. Vitro et al., Court of Appeals of Barcelona, 8 April 2021, Appeal Docket No. 1969/2020 On 8 April 2021, the Court of Appeals of Barcelona rendered judgment on appeal in a complex case relating to nucleic acid amplification primers for PCR-based clonality studies, involving a number of issues regarding the […]
READ MOREPosted: November 18th, 2021
Nutrition Sciences N.V. v. Kuminda N B.V., Court of Appeal, The Hague, The Netherlands, 29 June 2021, Case no. ECLI:NL:GHDHA:2021:2055 Nutrition is active in the field of ingredients for live stock feed and alleged that Noba infringes on the Dutch part of its EP 1 294 371 B2 relating to “medium chain fatty acids applicable […]
READ MOREPosted: August 14th, 2021
Interdigital Technology Corp and others v Lenovo Group Ltd and others [2021] EWHC 2152 (Pat) Background This judgment, handed down on 29 July 2021, concerned the validity and essentiality of EP (UK) 2 485 558 (“EP 558”). HHJ Hacon’s judgment is the first technical trial in a series of trials concerning five SEPs asserted by […]
READ MORE
EMAIL US
Array
(
[type] => 1
[message] => Uncaught Exception: Template 'templates/form/web/widgets/#type.html' not found ! in /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/helpers/render_engine.php:723
Stack trace:
#0 /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/helpers/render_engine.php(454): WYSIJA_help_render_engine->_loadTemplate('templates/form/...')
#1 /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/helpers/render_engine.php(169): WYSIJA_help_render_engine->_parse('\n{include file=...')
#2 /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/helpers/form_engine.php(756): WYSIJA_help_render_engine->render(Array, 'templates/form/...')
#3 /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/helpers/form_engine.php(638): WYSIJA_help_form_engine->render_web_body()
#4 /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/views/front/widget_nl.php(160): WYSIJA_help_form_engine->render_web()
#5 /home/a5j69q2zrgin/public_html/wp-content/plu
[file] => /home/a5j69q2zrgin/public_html/wp-content/plugins/wysija-newsletters/helpers/render_engine.php
[line] => 723
)